Table 2 Characteristics of patients with and without early VA failure

Age (years)

66.9 ± 14.6

70.7 ± 15.6

0.0819

Male (%)

65.2

49.1

0.0225*

Diabetes (%)

45.0

52.8

0.2854

Hypertension (%)

68.3

62.3

0.3770

Atrial fibrillation (%)

8.3

15.1

0.1128

 Exacerbation of CRF (%)

64.1

54.7

0.1832

 Heart disease (%)

13.6

17.0

0.5081

 Heart failure (%)

9.9

15.1

0.2535

 Coronary artery disease (%)

2.4

1.9

0.8309

 Infectious disease (%)

6.5

9.4

0.4366

 Malignancy (%)

3.4

3.8

0.8898

 Cephalopathy (%)

2.6

3.8

0.6302

 Cerebral infarction (%)

0.5

1.9

0.2611

 Intracranial hemorrhage (%)

1.0

0.0

0.4542

 Peripheral artery disease (%)

0.5

1.9

0.2611

 Aortic disease (%)

1.0

0.0

0.4542

 Others (%)

8.1

9.4

0.7440

Warfarin (%)

9.7

11.3

0.7086

Antiplatelet agent (%)

31.2

32.1

0.8919

Statin (%)

32.2

30.2

0.7687

ACEi or ARB (%)

46.9

41.5

0.4642

Beta blocker (%)

34.0

34.0

0.9921

CCB (%)

60.0

60.4

0.9523

LVEF (%)

55.6 ± 12.9

56.5 ± 12.7

0.7022

SBP (mmHg)

138.6 ± 24.2

132.1 ± 23.7

0.0671

DBP (mmHg)

75.1 ± 16.2

69.1 ± 17.3

0.0119*

WBC (10³/μL)

7.2 ± 3.2

8.0 ± 3.5

0.0870

Hb (g/dL)

9.8 ± 1.7

9.7 ± 1.9

0.6712

PLT (10⁴/μL)

19.2 ± 7.8

19.7 ± 8.3

0.6834

TP (g/dL)

6.1 ± 0.9

5.9 ± 1.0

0.1570

ALB (g/dL)

3.0 ± 0.6

2.7 ± 0.8

0.0002**

BUN (mg/dL)

68.5 ± 28.7

63.0 ± 34.2

0.2035

Cr (mg/dL)

7.3 ± 3.0

6.4 ± 2.4

0.0414*

eGFR (mL/min/1.7 m²)

7.3 ± 3.9

7.6 ± 3.6

0.6209

AST (IU/L)

23.2 ± 20.0

25.8 ± 24.9

0.3891

ALT (IU/L)

18.9 ± 21.3

17.7 ± 21.4

0.7076

CRP (mg/dL)

2.2 ± 3.3

3.2 ± 4.4

0.0390*

APTT

30.2 ± 9.7

31.2 ± 8.1

0.5918

PT-INR

1.16 ± 0.40

1.16 ± 0.20

0.9994

AVF (%)

77.5

66.0

0.0671